SOURCE: Cellceutix


August 03, 2015 09:14 ET

Cellceutix Announces Ongoing Enrollment of Phase 2 Trial of Brilacidin for Oral Mucositis

BEVERLY, MA--(Marketwired - August 03, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce the selection and addition of two clinical sites to be joining the Company's ongoing Phase 2 clinical trial of Brilacidin-OM for the treatment and prevention of oral mucositis in patients with head and neck cancer. Cellceutix expects recruitment to commence in the coming weeks at the centers, bringing the total number of clinical sites in the study to date to five.

Increasing patient access to the trial is important in the Company's efforts to discover an effective, safe therapy for oral mucositis and also to prove the anti-inflammatory properties of Brilacidin in a clinical setting. Laboratory studies have shown Brilacidin to have antibacterial and anti-inflammatory properties. Two successfully completed Phase 2 clinical trials of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) have demonstrated Brilacidin's ability to rapidly destroy bacteria.

"We are already confident in Brilacidin's anti-infective properties and believe it will be a true breakthrough if Brilacidin works as an anti-inflammatory as well," commented Leo Ehrlich, Chief Executive Officer at Cellceutix. "This trial has many implications because, as large as the anti-infective market is, the anti-inflammatory market potential for Brilacidin is even greater. I think it is important for shareholders to understand this and the potential value it brings to the Company. As we collect and analyze data from this trial, it will provide direction in our goal to initiate trials addressing the anti-inflammatory markets. Overall, I am very pleased and excited by what I have seen to date in all of our clinical trials and look forward to providing shareholders with a more comprehensive update upon receipt of additional data from all the participating vendors and clinical sites."

Sign-up for Cellceutix email alerts is available at

About Cellceutix:
Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antimicrobial applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol is being readied for a Phase 2 trial scheduled to begin July 28, 2015. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at

Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Cellceutix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. Cellceutix has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Cellceutix's need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that Cellceutix's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in Cellceutix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Cellceutix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

Contact Information

    Cellceutix Corporation
    Leo Ehrlich
    Email contact